| Literature DB >> 32300530 |
Makoto Isono1, Kenji Seguchi2, Masanori Yamanaka2, Kosuke Miyai3, Kazuki Okubo1, Keiichi Ito1.
Abstract
We report a case of unusually aggressive behavior of a mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney with no sarcomatoid changes. A 43-year-old man was referred to our hospital for a mass on his left kidney. Computed tomography revealed a tumor at the upper pole of the kidney and swollen lymph nodes. Left radical nephrectomy with lymph node dissection was performed and the tumor was diagnosed as MTSCC. Peritoneal dissemination was detected 4 months after the surgery. The patient received systemic treatments, which were not effective. He finally died of the disease 12 months after the surgery.Entities:
Keywords: Metastasis; Mucinous tubular and spindle cell carcinoma; Renal cell carcinoma; Sunitinib
Year: 2020 PMID: 32300530 PMCID: PMC7150526 DOI: 10.1016/j.eucr.2020.101162
Source DB: PubMed Journal: Urol Case Rep ISSN: 2214-4420
Fig. 1Abdominal CT and MRI at presentation.
T2-weighed MRI showing a tumor in the superior pole of the left kidney (A, arrow). CT showing a mass of the left kidney (B, arrows). The paraaortic lymph node were markedly swollen (C, arrow).
Fig. 2Histopathological features of MTSCC of the kidneys.
Macroscope image of the surgically resected specimen (A). Microscopic findings showing neoplastic tubules and cords embedded in a mucinous background (B, magnification: × 40, × 100, × 200). A subset of tumor cells showing nuclear pleomorphism with prominent nucleoli (B, magnification: × 200). Mucin production of the tumor cells observed via alcian blue staining (C, magnification: × 200). Immunohistochemical staining showing that the tumor was positive for AMACR (D, left, magnification: × 200) and PAX8 (D, right, magnification: × 200). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 3CT after surgery.
CT showing peritoneal dissemination 4 months after surgery (A, arrow) and the disseminated tumor shrinkage after sunitinib administration (B, arrow).